|Domain||Inclusion criteria||Exclusion criteria|
|Participants||Healthy human subjects undergoing any kind of active orthodontic treatment with orthodontic appliances.||
• Animal subjects undergoing any kind of orthodontic tooth movement.|
• Human subjects after the cessation of active orthodontic tooth movement, or unhealthy human subjects suffering from syndromes or systematic diseases.
|Interventions||Local or systemic administration of common biological agents (growth hormone, prostaglandins, parathyroid hormone, thyroxine, relaxin, vitamin D, platelet-rich plasma) to accelerate the rate of OTM||
• Studies where the active substance or another intervention was used to decelerate OTM.|
• The use of other interventions to accelerate OTM including (surgical interventions, e.g. corticotomies, micro-osteoperforations, piezocisions, the use of low-level energy laser and vibration)
▪ The local or systemic administration of drugs that are manufactured through chemical synthesis by combining specific chemical ingredients which are not considered biologics and might include bisphosphonates, non-steroidal anti-inflammatory drugs (NSAIDS), immunosuppressants, anti-cancerous drugs and anticonvulsants.
|Comparisons||Placebo intervention (preferably) or no intervention or administration of different dosages of the investigated substance.|
|Outcomes||Qualitative and quantitative data if possible regarding the rate of orthodontic tooth movement (i.e. the amount of tooth movement in a specific period of time) measured by various ways (callipers, feeler gauges, lateral cephalometric or panoramic radiographs, cone beam computerized tomography, digital or stone study models, etc.).|
|Study design||Experimental prospective controlled studies (randomized and non-randomized)||
▪ Non-comparative studies.|
▪ In vitro or ex vivo studies.
▪ Case reports, reviews, systematic reviews, and meta-analyses, case series, animal studies, opinion articles, and letters from editor